Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers

Savolitinib has shown good tolerability and preliminary efficacy, but efficacy biomarkers require investigation. The main purpose of this study was to confirm in Chinese patients the recommended phase II dose (RP2D) of savolitinib and to explore overall benefit in tumors bearing c-Met aberration. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2022-05, Vol.27 (5), p.342-e383
Hauptverfasser: Wang, Yakun, Liu, Tianshu, Chen, Gongyan, Gong, Jifang, Bai, Yuxian, Zhang, Tao, Xu, Nong, Liu, Li, Xu, Jianming, He, Jianxing, Liu, Yunpeng, Zhang, Li, Jiang, Da, Wang, Mengzhao, Chang, Jianhua, Li, Wei, Bai, Chunmei, Zhou, Jinghong, Wang, Jian, Ren, Yongxin, Zhang, Liya, Su, Weiguo, Liu, Baorui, Shen, Lin
Format: Artikel
Sprache:eng
Schlagworte:
Biological markers
Cancer
Cancer patients
Care and treatment
Clinical Trial Results
Complications and side effects
Crizotinib
Diagnosis
Drug therapy
Genetic aspects
Immunohistochemistry
Lung cancer, Non-small cell
Medical research
Medicine, Experimental
Nausea
Stomach cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Schreiben Sie den ersten Kommentar!
Bitte loggen Sie sich zuerst ein